user avatar
FabriceAndre
@FAndreMD
Head of Research Division of @GustaveRoussy , @myesmo President Elect
Joined October 2015
500
Following
15.1K
Followers
Posts
  • user avatar
    FabriceAndre
    @FAndreMD
    Jun 30, 2022
    Thank you to the @myESMO community to have elected me President. Digital / molecular tools to optimize care & integrating science to medical decision will be the main pillars of the vision, with the aim to improve outcome, decrease tox and decrease healthcare disparities. 1/3
  • user avatar
    FabriceAndre
    @FAndreMD
    Feb 11, 2020
    V happy to become Head of Research @GustaveRoussy : 500 staff, 10 highly cited researchers, 8 NEJM / Nature in 2019 as lead author.
    user avatar
    Gustave Roussy
    @GustaveRoussy
    Feb 11, 2020
    Le Pr Fabrice André est nommé Directeur de la Recherche de @GustaveRoussy par la Ministre des Solidarités et de la Santé @agnesbuzyn et par la Ministre de l'Enseignement supérieur, de la Recherche et de l'Innovation @VidalFrederique, pour cinq ans. ▶️gustaveroussy.fr/fr/le-pr-fabri…
  • user avatar
    FabriceAndre
    @FAndreMD
    Dec 18, 2022
    Argentina won the world cup (deserved) but the two teams together won the title of best game ever in a world cup. Thanks to them !
    42K
  • user avatar
    FabriceAndre
    @FAndreMD
    Jun 30, 2021
    The new Impact Factor @annals_oncology is 32. It means the papers we publish are highly cited and, given our Editorial scope, probably impact patient's outcome. Remember that all articles are free for @myesmo members ! Thank you all for your contributions !
  • user avatar
    FabriceAndre
    @FAndreMD
    Nov 13, 2021
    I'm very honored to receive the 2021 Outstanding Investigator Award for Breast Cancer Research from the American Association for Cancer Research @AACR at SABCS21.
    user avatar
    SABCS
    @SABCSSanAntonio
    Nov 12, 2021
    Helen Piwnica-Worms, PhD and Fabrice André, MD, PhD are the #SABCS21 recipients of the @AACR awards for their contributions to breast cancer research. See more at our blog. sabcs.org/2021-SABCS-sup…
  • user avatar
    FabriceAndre
    @FAndreMD
    Jun 29, 2020
    New Impact Factor of @Annals_Oncology is 18.2. This means our articles are more and more cited every year. Thanks a lot to all the Authors, Staff, Editors and Reviewers to make our journal better. High quality publication and dissemination ultimately improves patient management
  • user avatar
    FabriceAndre
    @FAndreMD
    Aug 31, 2022
    The presentation: "Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study" has just been added to the Presidential session III of #ESMO2022 First randomized trial testing a KRAS inhibitor in NSCLC
  • user avatar
    FabriceAndre
    @FAndreMD
    Sep 27, 2020
    This is the best review I ve read so far in the field of AI applied to cancer pathology. If you have few minutes, you should read it at rdcu.be/b7LqP . As always with @NatRevClinOncol , the figures are outstanding
  • user avatar
    FabriceAndre
    @FAndreMD
    Nov 14, 2022
    After 5 years, it’s time to leave the position of Editor in Chief of @Annals_Oncology . Call for applications is now open for the next EiC Tks to everyone, esp authors & reviewers. The journal has a now clear Editorial line & we are confident that we help improving patient care
  • user avatar
    FabriceAndre
    @FAndreMD
    Sep 24, 2020
    .@GustaveRoussy ranked 5th oncology hospital in the world by @Newsweek We all know the limitations of these rankings and that all big centers are very similar, but it probably means we are doing a good work for pts and research newsweek.com/worlds-best-sp…
  • user avatar
    FabriceAndre
    @FAndreMD
    Nov 23, 2020
    we are very pleased to announce that papers published in @Annals_Oncology are now free for patients. thanks @myESMO and @ELS_Oncology . To get a paper; go to annalsofoncology.org and request it thanks to the link mentioned below
  • user avatar
    FabriceAndre
    @FAndreMD
    Jun 6, 2021
    we have been AGAIN forbidden to share our genomic data on open portals, because of the "per-project re-consent" of GDPR. Frustrating for pts, clinicians and researchers who want to share their data to generate societal advances. Claim for open science is not compatible w GDPR
  • user avatar
    FabriceAndre
    @FAndreMD
    Feb 1, 2024
    Metastatic cancers should be classified as much as possible based on their biology, and agnostic of organ of origin To reach this vision, new statistical tools are needed to claim that drugs work across multiple cancers TY @Nature & @lucy_os for the opportunity to write about it
    user avatar
    nature
    @Nature
    Jan 31, 2024
    The conventional way of classifying metastatic cancers according to their organ of origin is denying people access to drugs that could help them. We need radical changes in how medical oncology is structured, conducted, and taught go.nature.com/3SEB7vb
    108K
  • user avatar
    FabriceAndre
    @FAndreMD
    Apr 18, 2022
    To authors who submit a paper @Annals_Oncology ; there is a procedure for presubmission inquiry. you can get a quick answer without formatting your paper. it's waste of resources if brains who should focus on research & care spend hours to format ms rejected without review.